Here at Bears Wire, we're going position by position to break down where Chicago stands entering the 2025 NFL draft. Next up ...

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year.

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson & Johnson CEO Joaquin Duato said.

Johnson & Johnson (JNJ) anticipates a $400M tariff impact by 2025 due to new trade levies, mainly slapped on MedTech goods.

Discover insights from Johnson & Johnson's Q1 2025 earnings call, highlighting 4.2% sales growth, MedTech innovation, and strategies to offset ...

While J&J expects tariffs will cost it $400 million this year, the company maintained its earnings estimate and upped its ...

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

By Patrick Wingrove and Bhanvi Satija (Reuters) -Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain disruptions and that favorable ...

Healthcare and medical technology company Johnson & Johnson (JNJ) has reported first-quarter financial results that beat Wall Street ...

"This transition marks a pivotal moment in Next Street's twenty-year journey," said Charisse Conanan Johnson, newly appointed CEO. "I am honored to lead our exceptional team as we build a thriving ...

Says that if U.S. wants manufacturing to return ‘the most effective answer is not tariffs, it’s tax policy.’Stay Ahead of the Market: Discover ...